We investigated the hypolipidemic effects of Melissa officinalis essential oil (MOEO) in human APOE2 transgenic mice and lipid-loaded HepG2 cells. Plasma TG concentrations were significantly less in APOE2 mice orally administered MOEO (12.5 mg/d) for 2 wk than in the vehicle-treated group. Cellular TG and cholesterol concentrations were also significantly 
Introduction
Hypertriglyceridemia is one of the main contributors to the development of cardiovascular disease (1) . Fibrates and niacin are available to treat hypertriglyceridemia, but these compounds are not as effective as statins at lowering cholesterol concentrations and are often associated with tolerance and side-effect issues (2) (3) (4) (5) (6) . Accordingly, efforts have focused on prevention strategies, potentially involving phytochemical-based dietary approaches. A reduction in fasting TG concentrations of 1 mmol/L could reduce the cardiovascular disease risk by 25% and could be achieved by dietary interventions (7) . This level of reduction could be achieved by intake of appropriate phytochemicals.
Recently, our laboratory reported that fragrant herbal essential oils produced significant metabolic effects in vivo. Terpenoids from herbal essential oils produced hypolipidemic effects by inhibiting hepatic cholesterol biosynthesis and cholesterol nucleation in bile. We showed that Plantago asiatica essential oil suppressed the mRNA and protein expression of HMG-CoA reductase in both HepG2 cells and C57BL/6J mice (8) ; that MOEO 4 produced antidiabetic effects, improving glucose tolerance and regulating the hepatic expression of genes involved in gluconeogenesis (9) ; and that wormwood (Artemisia princeps) essential oil displayed potent antioxidative and hypocholesterolemic activities (10) . Among plant sources of essential oils, MO is a well-known medicinal herb that has been used for a long time and has been suggested to be effective in the treatment of multiple conditions, including headaches, gastrointestinal disorders, nervousness, and rheumatism (11) . Moreover, MO has shown the potential to prevent and attenuate hyperlipidemia, reducing total serum lipid concentrations and levels of lipid peroxidation in the livers of hyperlipidemic rats (12) . However, the mechanisms underlying these lipid-lowering effects remain largely unknown. MO contains terpenoids, polyphenolics, and flavonoids (13) (14) (15) . On average, a cup of MO tea (0.15 L) contains~10 mg/L of essential oil (14) ; accordingly, drinking 2-3 cups of MO tea (0.3-0.45 L) daily may improve metabolic parameters such as plasma cholesterol and TG levels in humans (9) . Evidence exists that herbal essential oils have various pharmacological effects that can be attributed to the volatile and terpenoid compounds they contain, which include geranial, cineol, linalool, and caffeic acid (8) (9) (10) 16) .
Whereas drugs produce potent and specific effects, but potentially cause toxicity, nutrients and food molecules often produce multiple, more modest effects with high safety. Therefore, investigating the responses to nutrients is sometimes difficult, because evaluating and defining the effects of novel phytochemicals is hindered by the complexity and diversity in the signals they activate. Sometimes, a phytochemical induces a net hypolipidemic effect by activating multiple independent responses (e.g., effects on lipid synthesis, lipid oxidation, dietary lipid uptake, and plasma lipid removal). Thus, simultaneously assessing various components of the biological response is highly advantageous. Until recently, nutritional efficacy testing was based on selected biomarker approaches, which assess the levels of specific biomarkers under specific experimental conditions. However, such approaches do not provide global information. "Omics" techniques, notably the application of microarrays and high-throughput qPCR to gene biomarker research, allow a large number of biomarkers to be quantified, thus enabling the global effects of nutrients on cells to be evaluated (17) (18) (19) . The combination of selected biomarker and nutrigenomic approaches (20, 21) may allow for more accurate and profound mechanistic studies of phytochemicals. We therefore investigated the hypolipidemic effects of MOEO in vitro and in vivo through selected biomarker and transcriptome profiling approaches.
Materials and Methods
Preparation of MOEO. MO leaves were harvested at the Arboretum of Korea University (Seoul, Korea) and stored at -708C prior to the extraction of MOEO. The leaves (20 g) were then ground, steamdistilled, and simultaneously extracted in 0.5 L distilled water and 0.3 L diethyl ether. The extracts were dried over anhydrous Na 2 SO 4 and concentrated to a final volume of 300 mL using a gentle stream of N 2 gas.
Analysis of MOEO composition. GC-MS analysis was performed using a 6890N gas chromatograph (Agilent Technologies) and a Quattro GC/iontrap tandem mass spectrometer (Micromass) equipped with an AT-1701 capillary column (length = 50 m; i.d. = 0.25 mm, film thickness = 0.2 mm) (Alltech) as previously described (9) . The mass spectrometer settings were optimized to provide the best resolution at 69, 219, 502, and 614 m/z using perfluorotributylamine. Mass measurements in the range 33-350 m/z were obtained at 2408C using an EI-positive ion source in SCAN mode. Total ion chromatograms were analyzed using MassLynx 4.0 software (Micromass) and compounds were positively identified with the aid of the Wiley Mass Spectral Database (2002; John Wiley and Sons).
Animals and treatments. Male human APOE2 (R158C) transgenic mice (6-10 wk old; Taconic Farms) were used. APOE2 transgenic mice were generated by targeted replacement of the endogenous mouse Apoe gene with a human APOE2 allele. APOE2 mice develop extreme hypertriglyceridemia, accumulating TG-rich lipoproteins in the plasma (22) . Mice consumed regular rodent nonpurified diet (Purina Laboratory Rodent Nonpurified Diet 38057, Dyets, which contains 200 g/kg protein, 45 g/kg fat, 60 g/kg crude fiber, 72.5 g/kg ash, 15.37 MJ/kg energy, and sufficient amounts of minerals and vitamins for the maintenance of health) and water ad libitum under a 12-h-light/-dark cycle. APOE2 mice were divided into control and treatment groups. The mice in the treatment group received MOEO (12.5 mg/d) by oral gavage for 2 wk. A cup of MO tea contains 10 mg/L essential oil (14) ; thus, the dosage of MOEO used corresponds to 3-4 cups/d of MO tea (0.45-0.6 L) for adult men. The control mice were gavaged with an equivalent volume of vehicle. Following treatment, blood samples were obtained by cardiac puncture under general anesthesia with 2.5% tribromoethanol (0.02 L/kg, i.p.). The mice were then killed and their livers were removed, snap-frozen in liquid nitrogen, and stored at -808C prior to analysis. All experimental procedures involving mice were approved by the Institutional Animal Care and Use Committee of Korea University (animal protocol no. KUIACUC-20090421-2).
Plasma lipid analysis. Plasma was separated from whole blood by centrifugation (3000 3 g, 20 min). Plasma concentrations of TG, and total and LDL cholesterol were determined enzymatically using a cobas c 111 analyzer (Roche Diagnostic Systems).
Oligonucleotide microarray analysis. Two-color oligonucleotide microarray experiments were performed with livers from nontreated (control) and MOEO-treated APOE2 transgenic mice. Total RNA preparation, cDNA synthesis, hybridization, and data analysis was performed according to the previously published method (23) . We used pooled RNA samples from 4 livers of vehicle-treated mice for controls (n = 4) and 2 livers of MOEO-treated mice (n = 2) and performed an exploratory microarray experiment to identify pathways (n = 2). We used 38.8 K Mouse Exonic Evidence Based Oligonucleotide arrays (Stanford Functional Genomics Facility), which contain 30,125 constitutive exonic probes. Probe-level gene expression values were computed using GenePix 4.0 software and the Stanford Microarray Database. The data were normalized by NormExp (24) background correction (offset = 350) and by the Loess (25) and Aquantile (26) methods using Bioconductor limma software. Transcriptional responses to MOEO treatment were analyzed using the SAM method, implemented with Bioconductor samr software. The false discovery rate was set at 0.0005. Within SAM, log 2 -transformed expression data from the control and treatment groups were compared by Student's unpaired t tests. The effects of MOEO treatment on biological pathways were assessed by analyzing genes identified in SAM as being MOEO-regulated using the Database for Annotation, Visualization, and Integrated Discovery. Hierarchical clustering of lipid metabolism-associated genes identified by this pathway analysis was performed using Acuity 4.0 software (Axon Instruments).
Cell culture and treatments. HepG2 cells were grown in DMEM (Hyclone) supplemented with 10% heat-inactivated FBS (Hyclone) and 1% penicillin/streptomycin (WelGENE). Cells were subsequently seeded into 100-mm culture dishes or 6-well culture plates. After they reached confluence, they were cultured for 26 h in DMEM containing 10% FBS and 1% penicillin/streptomycin as well as oleate (40 mmol/L) and palmitate (40 mmol/L), which were conjugated to 0.16% fatty acid-free BSA to mimic hyperlipidemic conditions. After intracellular lipid droplets formed in the HepG2 cells, they were washed with PBS and then incubated with serum-free DMEM with or without 400 or 800 mg/ L MOEO for 12 or 24 h. These levels of essential oils have been shown to be nontoxic and biologically functional (27) . jn.nutrition.org min and rinsed thoroughly with distilled water. Stained lipid droplets were visualized using an Eclipse Ti inverted microscope (Nikon).
Measurement of cellular TG and total cholesterol concentrations.
HepG2 cells were washed with ice-cold PBS and cellular lipids were extracted at room temperature with 2 mL of a 2:1 (v:v) mixture of hexane and isopropanol. The organic solvent was removed by vacuum centrifugation and the lipids were resuspended in 200 mL 95% ethanol. TG and total cholesterol concentrations were enzymatically determined using the Cobas C111 analyzer and the concentrations were normalized with total protein concentrations.
Measurement of total bile acid concentration. Total bile acid concentrations were determined using a Total Bile Acid kit (Bio-Quant) according to the manufacturer's instructions (by an enzymatic method involving 3a-hydroxysteroid dehydrogenase) and normalized to total protein concentrations.
Real-time qPCR. Total RNA was extracted from individual livers and HepG2 cells using TRIzol Reagent according to the manufacturer's instructions. cDNA was synthesized from 2 mg total RNA using Superscript II reverse transcriptase (Invitrogen) and oligo(dT) primers. Levels of gene expression were measured using an iQ5 Real Time PCR Detection System (Bio-Rad) and Bio-Rad iQ SYBR Green Supermix reagent. Relative levels of gene expression were calculated using iQ5 Optical System Software version 2 (Bio-Rad), with the expression of each target gene being normalized to that of b-actin or GAPDH. The primer sequences are shown in Supplemental Table 1 .
Immunoblotting. Total protein samples were prepared as previously described (10) . Sample protein content was determined using a BCA Protein Assay kit (Pierce). Protein samples (30 mg) were subjected to 10% SDS-PAGE and then transferred to and immobilized on nitrocellulose membranes. After blocking, the membranes were probed with primary antibody [anti-SREBP-2, anti-SREBP-1, anti-FAS, anti-ACC1, anti-Insig-1, anti-SCAP, anti-a-tubulin (all from Santa Cruz Biotechnology), or anti-SCD1 (Alpha Diagnostic International)] and then incubated with secondary antibody (anti-rabbit IgG-HRP or anti-mouse IgG-HRP, Santa Cruz Biotechnology). Immunoreactive bands were imaged with a ChemiDoc XRS imaging system (Bio-Rad) using PowerOpti-ECL Western blotting detection reagent (Anigen). The relative band intensities were determined using Gel-Pro Analyzer 4.0 software (Media Cybernetics). For each sample, target protein levels were normalized to that of a-tubulin (internal reference).
ChIP assay. ChIP assays were performed using an EZ ChIP kit (Millipore) according to the manufacturer's instructions, with modifications. After fixing in 2% formaldehyde. The nuclear DNA were fragmented to 200-1000 bp in length by sonication, then lysates were centrifuged (3000 3 g, 10 min) and the supernatants were subjected to immunoprecipitation with antisera specific for PCAF (Santa Cruz Biotechnology), H3K14 (Upstate Biotechnology), and acetyl-H3K14 (Upstate Biotechnology). IgG (Upstate Biotechnology) was used as a negative control for nonspecific antibody binding. Immunoprecipitated protein-DNA complexes were incubated with NaCl to reverse the formaldehyde cross-links. DNA was recovered using an AxyPrep PCR Cleanup kit (Axygen) and was then used as the template for standard PCR reactions. The signal for each sample was normalized to that for the input control. Supplemental Table 1 shows the sequences of the primers used. These primers are specific for PCAF-and H3K14ac-binding sites adjacent to the SRE sequences in the promoters of ACC1, FAS, and SCD1.
Fatty acid oxidation and fatty acid synthesis. Fatty acid oxidation was measured with [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]palmitate in mouse plasma samples and HepG2 cells as previously described (28) . Plasma b-hydroxybutyrate concentrations were measured using a b-Hydroxybutyrate Assay kit (BioVision) according to the manufacturer's instructions. The synthesis of fatty acids from [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]acetate (45-60 mCi/mmol; Perkin Elmer) was examined according to a previously described method (29) .
Statistical analysis.
was used to examine the correlation between expression changes in microarray and qPCR analyses. P , 0.05 was considered significant.
Results
Chemical composition of MOEO. The main constituents of MOEO are the oxygenated monoterpenes geranial, neral, and geranyl acetate. MOEO also contains smaller amounts of bpinene, linalool, and caryophyllene ( Table 1) .
Plasma TG and cholesterol concentrations in MOEO-fed APOE2 mice. After treatment for 2 wk, plasma TG concentrations were lower in MOEO-fed APOE2 mice than in vehicletreated controls (P , 0.05) (Fig. 1A) . MOEO treatment also tended to reduce plasma total cholesterol concentrations (by 24%, P = 0.08) compared to controls; however, LDL cholesterol concentrations not differ between the groups (218%; P = 0.3) (Fig. 1A) . In lipid-loaded HepG2 cells, which mimic hyperlipidemic conditions in an in vitro system, MOEO reduced cellular TG and total cholesterol concentrations in a dose-and time-dependent manner (P , 0.05) (Fig. 1B,C) . Oil Red O staining yielded similar results (Fig. 1B,C) . Treatment with MOEO at 800 mg/L for 24 h reduced cellular TG and total cholesterol concentrations in hepatocytes by 32 and 27%, respectively (P , 0.05) (Fig. 1B) and 800 mg/L was the highest nontoxic concentration of MOEO in HepG2 cells, as shown by the results of a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay (data not shown).
Hepatic transcriptome analysis in MOEO-fed APOE2 mice. In total, 2178 upregulated transcripts and 1444 downregulated transcripts were identified by SAM in MOEO-fed mice. Pathway analysis of genes whose expression was significantly altered following treatment with MOEO revealed that 4 lipid metabolism pathways, cholesterol synthesis, bile acid synthesis, fatty acid oxidation, and fatty acid synthesis, were significantly altered. Clustering analysis revealed that the expression of major lipid metabolism-associated genes (64 genes) was strongly altered following MOEO treatment (Supplemental Fig. 1 ). The expression of 11 of these 64 genes identified based on preliminary microarray comparison was measured by real-time qPCR, the results of which validated the microarray data (Supplemental Fig. 2) . The microarray data showed that the expression of the Cyp7b1, and Hsd3b7 genes, which contribute to bile acid synthesis, was greater in MOEO-fed mice than in controls. MOEO also increased the expression of the fatty acid oxidation pathway genes, including Acaa2, Ech1, and Cel compared to controls. However, it reduced the expression of the fatty acid synthesis pathway gene, including Srebf-1c by 22%, and that of the SREBP-1c target genes Fas, Scd1, and Acc1 by 27, 32, and 32%, respectively, compared to controls. The mRNA expression of the SREBP-1c coactivators Pcaf and Sp1 was also lower in MOEO-fed mice than in controls (by 27% for Pcaf and 22% for Sp1). In addition, Vldlr expression was significantly induced by MOEO treatment compared to controls (microarray analysis). In real-time qPCR analyses, the expression patterns of the selected genes were similar to those in the microarray analysis, and the real-time qPCR and microarray data were positively correlated (r = 0.88; P , 0.01) (Supplemental Fig. 2) . The mRNA expression of the selected genes in HepG2 cells treated with 800 mg/L MOEO was assessed by real-time qPCR. The expression patterns were similar to those in the mouse livers (Supplemental Fig. 3 ).
Effects of MOEO on hepatic cholesterol metabolism. After 2 wk of oral administration of MOEO (12.5 mg/d) in APOE2 mice, the cholesterol concentrations were not significantly altered in the MOEO group compared with the vehicle-treated control group. However, because the pathway analysis with microarray suggested the possibility of alteration of cholesterol and bile acid synthesis pathways, we further explored the potential effects of MOEO on cholesterol metabolism in lipidloaded HepG2 cells. Treatment with 400 and 800 mg/L MOEO for 24 h increased total bile acid synthesis 4.2-and 7.2-fold, respectively, compared to the control (P , 0.05) ( Fig. 2A) in part 1 n = 1. MOEO, Melissa officinalis essential oil; t, trace amount (,0.05% of the total peak area). by increasing the expression of CYP7b1 and HSD3b7, as suggested by real-time qPCR data (Supplemental Fig. 3 ). We additionally examined the expression of SREBP-2 and its target gene HMG-CoA reductase for cholesterol synthesis in cultured hepatocytes. MOEO dose-dependently reduced HMGCoA reductase expression (by 14 and 21% at 400 and 800 mg/L, respectively) (P , 0.05) (Fig. 2B) . It did not change SREBP-2 gene expression but did increase levels of the precursor form of SREBP-2 and significantly reduced levels of the mature, nuclear form of SREBP-2 (nSREBP-2) by 25 and 64% at MOEO concentrations of 400 and 800 mg/L, respectively (P , 0.05) (Fig. 2C,D) . Total SREBP-2 levels were similar in the MOEO and control groups. The reduction in the mRNA expression of HMG-CoA reductase resulted from reduced nuclear translocation of SREBP-2, although SREBP-2 mRNA levels did not decrease, as shown by the results of the microarray and real-time qPCR analyses. These findings collectively suggest that MOEO may regulate hepatic cholesterol metabolism by inducing the degradation of cholesterol into bile acids and reducing cholesterol synthesis.
Hypotriglyceridemic mechanisms in hepatocytes: reduction of fatty acid synthesis. TG-lowering effects of MOEO were further studied in the context of the regulation of fatty acid oxidation and synthesis on the basis of the microarray data. MOEO did not alter plasma concentrations of b-hydroxybutyrate, an indicator of hepatic fatty acid oxidation, in APOE2 transgenic mice compared to controls (Supplemental Fig. 4) . In a second experiment in which lipid-loaded HepG2 cells were exposed to [1- 14 C]palmitate, the rate of fatty acid oxidation was similar in the MOEO and control groups (Supplemental Fig. 4) .
Next, the expression of genes involved in fatty acid synthesis was quantified. In HepG2 cells, MOEO reduced the mRNA expression of SREBP-1c and its target genes FAS, SCD1, and ACC1 in a dose-dependent manner (Fig. 3A) . The expression of SREBP-1c target genes involved in fatty acid synthesis yielded similar results to those obtained in mouse experiments. Moreover, the levels of nSREBP-1c were lower in MOEO-treated cells than in control cells by 24 and 69% with 400 and 800 mg/L MOEO, respectively (P , 0.05) (Fig. 3B) . The expression of two auxiliary proteins in the nuclear translocation of SREBP, SCAP, and INSIG-1 was assessed. In HepG2 cells, 800 mg/L MOEO reduced SCAP mRNA and protein expression by 53 and 86%, respectively (P , 0.05), while inducing INSIG-1 mRNA and protein expression by 99 and 66%, respectively (P , 0.05) (Fig.  3C ). These responses may explain the observed reduction in the nuclear translocation of SREBP-1c by MOEO, as suggested by Horton et al. (30) . The observed decrease in nSREBP-1c levels may significantly suppress the mRNA expression of SREBP-1c-responsive genes (Fig. 3A) , ultimately reducing their protein levels (Fig. 3B) . The higher concentration of MOEO (800 mg/L) reduced the protein expression of FAS, SCD1, and ACC1 in HepG2 cells by 56, 86, and 60%, respectively, compared to controls (P , 0.05) (Fig. 3D) .
ChIP assay analysis of liver tissues from APOE2 transgenic mice showed that the reduced expression of Fas, Scd1, and Acc1 was associated with downregulation of H3K14ac and suppression of the binding of the histone acetylase PCAF to SRE sequences in 3 SREBP-1c target genes. Compared to controls, MOEO reduced the binding of PCAF to SRE sequences in the Fas, Scd1, and Acc1 genes by 46, 52, and 30%, respectively, and suppressed H3K14ac in the Fas, Scd1, and Acc1 promoters by 29, 42, and 36%, respectively, thereby downregulating the expression of Fas, Scd1, and Acc1 (Fig. 3E) . The expression of FAS, SCD1, and ACC1 was similar in HepG2 cells and the livers of APOE2 transgenic mice. MOEO at 800 mg/L significantly reduced PCAF binding by 32% and H3K14ac in the promoters of the FAS gene by 27%, respectively, the SCD1 gene (19 and 39%, respectively), and the ACC1 gene (11 and 13%, respectively) compared to controls (P , 0.05) (Fig. 3F) . These responses ultimately led to reductions in fatty acid synthesis in HepG2 cells treated with 400 and 800 mg/L MOEO of 49 and FIGURE 2 Cellular bile acid concentrations (A), SREBP-2 and HMG-CoA reductase mRNA levels (B), and levels of the nuclear (n) and precursor (p) forms of SREBP-2 (C, D) in non-and MOEO-treated HepG2 cells. Data are mean 6 SEM, n = 3. In A, B, and D, means without a common letter differ, P , 0.05. HMG-CoA reductase, 3-hydroxy-3-methyl-glutaryl-CoA; MOEO, Melissa officinalis essential oil; nSREBP-2, nuclear form of SREBP-2.
DISCUSSION
We investigated the hypolipidemic effects of MOEO in vitro and in vivo using lipid-loaded HepG2 cells and human APOE2 transgenic mice, respectively. Oligonucleotide microarrays were used to analyze hypolipidemic pathways regulated by MOEO feeding in mice. The effects of MOEO were also investigated by a selected biomarker approach in lipid-loaded HepG2 cells and APOE2 transgenic mouse livers. APOE2 transgenic mice, which specifically express the human APOE2 gene as a result of targeted replacement of the endogenous mouse Apoe gene, are defective in VLDL clearance, and spontaneously develop hypertriglyceridemia and hypercholesterolemia (22) . Hepatic lipid accumulation and liver steatosis often develop in APOE2 transgenic mice, while evidence exists that lipid loading in cultured cells mimics hyperlipidemic conditions (31) . Accordingly, we used APOE2 mice and lipid-loaded hepatocytes as in vivo and in vitro systems in our experiments. High concentrations of fatty acids, notably oleic acid and palmitate, are commonly used to induce lipid accumulation in cultured hepatocytes (32) . Oleic acid is widely used to induce lipid accumulation, because it is a major plasma and tissue lipid and produces color-stable lipid droplets (32) . Thus, we used a fatty acid mixture containing palmitic acid and oleic acid to mimic hyperlipidemic conditions in HepG2 cells.
Active volatile compounds from essential oils have been detected in animal plasma in dose-dependent amounts after oral administration in vivo, suggesting that volatile essential oils such as MOEO are effectively delivered to internal organs after intake (33, 34) . We recently found that linalool, a bioactive constituent of MOEO, was effectively absorbed by human intestinal Caco-2 cells, as assessed in a Transwell assay (data not shown).
In APOE2 transgenic mice, treatment with MOEO for 2 wk did not significantly reduce total cholesterol concentrations. However, transcriptome analysis of mouse livers showed improved expression of cholesterol metabolism genes, whereas data from in vitro experiments showed reduced expression of HMC-CoA reductase and increased bile acid synthesis. However, it is still possible that some minor components of MOEO may have hypocholesterolemic effects or long-term feeding may have hypocholesterolemic effects.
The hypotriglyceridemic effects of MOEO were significant, because 2 wk of feeding reduced plasma TG concentrations by 36%. The detailed mechanisms were investigated in vitro and in vivo. The TG-lowering effects of MOEO were confirmed in two other mouse strains in addition to APOE2 transgenic mice. MOEO significantly reduced plasma TG concentrations in normal C57BL/6J mice and diabetic db/db mice by 34 and 27%, respectively, compared to controls (P , 0.05) (data not shown). Moreover, oral administration of geranial, the major constituent of MOEO, at a dose of 100 mg×kg 21 ×d 21 for 3 wk lowered lipid concentrations in C57BL/6J mice with high-fat diet-(60% energy from fat) induced hyperlipidemia (by 41%; P , 0.05), which suggests that geranial is one of the active compounds responsible for the hypolipidemic effects of MOEO. In addition, linalool, which was also detected in MOEO by GC-MS, may contribute to the cholesterol-and TG-lowering effects of MOEO, inducing significant reductions in plasma TG and LDL cholesterol concentrations (40 and 43%, respectively) in high-fat diet-(60% kcal from fat) fed C57BL/6J mice when administered at a dose of 120 mg×mouse 21 ×d 21 for 6 wk (P , 0.05; n = 6/group).
We showed that oral administration of MOEO for 2 wk ameliorated hyperlipidemia in APOE2 transgenic mice. The dose administered (12.5 mg/d for a 20 g mouse) corresponds to 0.6 mg/kg in humans. This dose of essential oil may be obtained from 0.25 g MO leaves, an amount whose ingestion has been shown to be nontoxic in animal and clinical studies (27, 35) . MO [1- has been used as a traditional medicinal plant since the Middle Ages in Europe (36) . No side effects or symptoms of toxicity have been reported (27, 35) . We ourselves observed no significant changes in toxicological pathways when we analyzed hepatic gene expression in MOEO-treated APOE2 transgenic mice using microarrays, confirming the safety of MOEO.
The hypotriglyceridemic mechanisms of MOEO are summarized in Figure 4 . First, the nuclear translocation of SREBP-1c is delayed, which itself results at least in part from the upregulation of INSIG-1 and downregulation of SCAP in the ER. Second, the reduction in nuclear SREBP-1c protein levels suppresses the expression of key genes in fatty acid synthesis, including FAS, SCD1, and ACC1. In addition, the recruitment of PCAF to SRE and H3K14 acetylation in the FAS, SCD1, and ACC1 promoters is reduced. These changes collectively reduce the rate of hepatic fatty acid synthesis. In previous studies, SREBP-1c and SREBP-1c responsive genes for fatty acid synthesis have been widely used as a target mechanism for regulation of plasma TG concentrations through dietary interventions (37) .
The nuclear translocation of SREBP-1c is regulated by a complicated mechanism. The downregulation of SCAP and upregulation of INSIG-1 have been reported to be 2 important factors (38) (39) (40) . SCAP is a molecular chaperone involved in the translocation of SREBP from the endoplasmic reticulum to the Golgi (41,42), whereas INSIG-1 delays SCAP-mediated SREBP translocation when cellular sterol concentrations are high (40) . Transgenic mice that overexpress human INSIG-1 and SCAPdeficient mice reportedly display reduced SREBP processing and lipogenesis (30, 39, 43, 44) . Treatment of hepatocytes with MOEO reduced SCAP expression and induced INSIG-1 expression, responses that could delay the nuclear translocation of SREBP and subsequent lipogenesis.
Hormones and nutrients have been suggested to modulate the transcription of target genes by altering histone acetylation and deacetylation (45, 46) . Coactivators with histone acetyltransferase activity bind to promoters with SREBP-1c and stimulate transcription in a gene-specific manner through localized hyperacetylation of the neighboring chromatin (47) . SREBP interacts with various coactivators, one of which (PCAF) is required for maximal target gene activation (48) (49) (50) . MOEO significantly reduced PCAF binding and H3K14ac in the promoters of the Fas, Scd1, and Acc1 genes. These responses may attenuate fatty acid synthesis by downregulating the expression of Fas, Scd1, and Acc1, thereby ameliorating hypertriglyceridemia in APOE2 transgenic mice.
Fatty acid oxidation was suggested by the results of the microarray and real-time qPCR analyses, and notably the expression patterns for Acaa2, Ech1, and Cel, to be a candidate TG-lowering mechanism. However, MOEO did not alter plasma b-hydroxybutyrate concentrations or the rate of fatty acid oxidation in lipid-loaded HepG2 cells. Thus, enhancing fatty acid oxidation may not be a key mechanism by which MOEO reduces TG concentrations.
To the best of our knowledge, this is the first study to investigate the hypolipidemic mechanisms of fragrant phytochemicals in vitro and in vivo using both selected biomarker and nutrigenomic approaches. Oral intake of MOEO may affect multiple hepatic lipid metabolism pathways. The hypotriglyceridemic effects of MOEO may result from reduced translocation of SREBP-1c and, subsequently, reduced expression of genes involved in fatty acid synthesis via decreased PCAF histone acetylase activity, which results in the reduction of hepatic fatty acid synthesis. These findings suggest that the intake of phytochemicals with pleasant odors could have beneficial metabolic effects. 
